UNSPSC 51285607: Lasalocid sodium

This classification denotes an antibiotic with the molecular formula C34H53O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W2S5C71Y3G, chemically known as 2,3-cresotic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyran-2-yl)tetrahydro-3-methyl-2-furyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-, monosodium salt. (-)- but more generally known as lasalocid sodium, which bears US NIH Compound Identifier 33265. Most nations schedule lasalocid sodium under HS 29419000.

As of Q4 2014, LASALOCID SODIUM remains the US FDA Preferred Term for this commodity. Lasalocid sodium bears US NLM identifiers UMLS ID C0878439 and NCI Concept Code C79535. SMILES: CC[C@H]([C@@H]1[C@H](C[C@@](O1)(CC)[C@H]2CC[C@@]([C@@H](O2)C)(CC)O)C)C(=O)[C@@H](C)[C@H]([C@H](C)CCC3CCC(C(C3C(=O)[O-])O)C)O.[NA+].

UNSPSC 51285607 Lasalocid sodium is a Commodity code that captures pharmaceutical active ingredients and specialized health-related chemical products, though the recent state and local opportunities associated with this code reflect a significant mismatch with its nominal scope. The opportunities posted under this code actually concern naloxone procurement and pharmaceutical warehouse supply contracts—products that fall outside lasalocid sodium's narrow pharmaceutical veterinary use case. State and local buyers posting under this code include health departments and county health agencies pursuing competitive acquisitions of finished pharmaceutical products and medical countermeasures through warehouse piggyback agreements and direct IFB processes. The mismatch suggests either catalog-tagging variance in state and local procurement systems or administrative routing of pharmaceutical acquisitions through a parent or subsidiary code that does not reflect the actual commodity being bought.

Activity on the code concentrates in the South and Midwest. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026 for doxycycline and ciprofloxacin supply through the MMCAP Infuse consortium, totaling $2,999,999.11 over the life of the three-year contract term. Seminole County, Florida posted an IFB (solicitation number IFB60459723LAS) on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; that opportunity closed July 26, 2023 (the due date reflects an apparent data error in the source). Both procurements used competitive sealed-bid processes with no stated set-aside designations. Business development professionals should verify their firm's coding assignment with state and local procurement offices before pursuing opportunities posted under this code, as the recent record shows limited alignment between the code's pharmaceutical scope and the actual health-supply and chemical products being bought.